Cardiovascular Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Albany College of Pharmacy & Pharmceut. Res. Inst.
Tissue factor pathway inhibitor aids the antiangiogenic effects of tinzaparin
December 7th, 2004
Tissue factor pathway inhibitor aids the antiangiogenic effects of tinzaparin. "Heparin and low molecular weight heparins (LMWHs) have both antithrombotic and antiangiogenic activities. The antiangiogenic activity of LMWH may be associated with the release of endothelial tissue factor pathway inhibitor (TFPI), an important endogenous inhibitor of tissue factor/Factor VIIa (TF/fVIIa)," researchers in the United States report. "To evaluate the effects of LMWH, tinzaparin, and TFPI in a model of angiogenesis-mediated processes, we compared the effects of tinzaparin and recombinant TFPI in inhibiting either basic fibroblast growth factor-2 (FGF2)- or...
Source: Cardiovascular Business Week (2004-12-07)
|
